OncoMatch/Clinical Trials/NCT05147844
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Is NCT05147844 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Toripalimab for nasopharyngeal carcinoma.
Treatment: Toripalimab — The aim of the study was to determine the efficacy and safety of toripalimab combined with radiotherapy in the treatment of oligometastatic nasopharyngeal carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVB
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: unsuitable or unwilling to receive chemotherapy according to the judgment of investigator
Unsuitable or unwilling to receive chemotherapy according to the judgment of investigator
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L, PLT ≥ 100×10^9/L, Hb ≥ 90g/L (have not accepted blood transfusion or growth factors within 14 days); INR or PT ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN
Kidney function
serum creatinine ≤ 1.5×ULN or estimated glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2
Liver function
total bilirubin ≤ 1.5×ULN (total bilirubin <3×ULN for patients with Gilbert syndrome); AST and ALT ≤ 2.5×ULN (AST and ALT ≤ 2.5×ULN for patients with liver metastasis)
Adequate organ function, defined as achieving the following laboratory test results within 7 days before enrollment: ANC≥1.5×10^9/L，PLT≥100×10^9/L，Hb≥90g/L((Have not accepted blood transfusion or growth factors within 14 days)；the international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; activated partial thromboplastin time(APTT) ≤1.5 × ULN；serum creatinine≤1.5×ULN or estimated glomerular filtration rate(GFR) ≥ 60 mL/min/1.73 m2; total bilirubin≤1.5×ULN（total bilirubin<3×ULN for patients with Gilbert syndrome）; AST and ALT ≤ 2.5×ULN (AST and ALT ≤ 2.5×ULN for patients with liver metastasis);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05147844 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IVB is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages